Aura Biosciences, Inc. Finance Lease, Right-of-Use Asset, Amortization
Aura Biosciences, Inc. (AURA) reported Finance Lease, Right-of-Use Asset, Amortization of $11.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2023-03-15
- Aura Biosciences, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-12-31 was $0.00.
- Aura Biosciences, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-09-30 was $0.00.
- Aura Biosciences, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-06-30 was $3.00K.
- Aura Biosciences, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-03-31 was $8.00K.
- Aura Biosciences, Inc. finance lease, right-of-use asset, amortization for fiscal 2021 was $11.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $3.00K derived: sum of 3 quarters · filed 2023-03-15 | $11.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.00K derived: sum of 2 quarters · filed 2022-11-10 | $11.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-11 | $11.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $8.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |